Predicting outcome in metastatic urothelial cancer (UC) receiving docetaxel (DT): miRNA profiling in pre and post therapy.

• DOI: 10.1200/jco.2015.33.15_suppl.e15518
• Publication Date: 2019-03-07T17:21:56Z
• Authors: Stephanie A. Mullane; Lillian Werner; Chensheng Willa Zhou; Mary-Ellen Taplin; Toni K. Choueiri; Joaquim Bellmunt; Michaela Bowden
• Keywords: Progression-free survival

e15518 Background: Docetaxel (DT) is used frequently as second line therapy in metastatic UC, despite low response rates. However, selected patients may derive significant benefit. Circulating miRNAs have been shown to predict DT castration-resistant prostate cancer (Lin et al, BJC 2014). We aimed determine if the same circulating UC. Methods: obtained pre and post plasma samples from included arm of a phase II clinical trial (n = 20). Total RNA was extracted RT-PCR performed on panel known be important (miR125, miR27a, miR34a, miR429, miR141, miR200a, miR200c, miR 146a, miR9). Samples were normalized individual miRNA median levels. analyzed based progression free survival (PFS) those with favorable outcomes ( > 2.5 mo PFS or 3 cycles) versus poor outcome < at first evaluation). Differences levels assessed using t test (p 0.05) by fold change (FC) (sig. |2|) between 2 groups. Results: Higher miR200a correlated longer pre-DT samples. miR125 had decrease (FC -3.9) good cohort, but not for group 0.93). Internal validation data will presented. Conclusions: Among predicting treatment cancer, are potentially useful biomarkers docetaxel optimization Further warranted.